Pressure offloading is one of the most powerful—and most frequently underused—interventions in the management of diabetic foot ulcers. A plantar neuropathic ulcer forms where repetitive mechanical stress meets a foot that can no longer feel it. Until that stress is removed, even meticulous wound care and antibiotics struggle to close the wound. Understanding how offloading works, which devices are supported by evidence, and why the best treatments are so often left on the shelf is central to preventing the amputations that follow non-healing ulcers.
Why offloading matters
Most diabetic foot ulcers on the sole of the foot are the product of two overlapping problems: peripheral neuropathy that blunts protective sensation, and abnormal plantar pressures created by deformity, limited joint mobility, and altered gait. Because the patient feels no pain, they continue to walk on the wound with every step, driving inflammation, disrupting new tissue, and keeping the ulcer open. Redistributing that pressure away from the wound restores the mechanical conditions healthy tissue needs to heal.
The stakes are high. According to a clinical practice guideline from the Society for Vascular Surgery, the American Podiatric Medical Association, and the Society for Vascular Medicine, offloading is one of five pillars of diabetic foot care alongside prevention, wound care, infection management, and revascularization (Hingorani et al., Journal of Vascular Surgery, 2016). Non-healing ulcers are the most common pathway to lower-limb amputation, which makes effective offloading a limb-preservation strategy, not merely a wound dressing add-on.
The evidence for non-removable devices
Decades of controlled research point to a clear hierarchy. For a plantar neuropathic forefoot ulcer without significant ischemia or infection, the International Working Group on the Diabetic Foot (IWGDF) recommends a non-removable, knee-high offloading device—either a total contact cast (TCC) or a non-removable knee-high walker rendered irremovable—as the first-choice treatment (Schaper et al., IWGDF Practical Guidelines, Diabetes/Metabolism Research and Reviews, 2020; updated methodology described by Bus et al., 2023).
The reason non-removable devices outperform removable ones is largely about adherence. A total contact cast fits snugly to the entire lower leg and foot, spreading load across a wide surface and, crucially, staying on. Removable boots achieve comparable pressure reduction in the laboratory but only work when worn, and patients frequently take them off. A biomechanical study comparing devices confirmed that the total contact cast and a braced removable cast produced significant peak plantar pressure reductions across most regions of the foot, reaffirming the TCC as the gold-standard reference (Carter et al., Journal of the American Podiatric Medical Association, 2025).
Newer casting materials may broaden access without sacrificing results. A retrospective comparison found that a non-removable total contact softcast achieved ulcer-healing rates comparable to conventional total contact casting, with a healing time that trended shorter, suggesting lighter and more tolerable casts warrant further study (Vierhout et al., Diabetes Research and Clinical Practice, 2022).
The evidence-to-practice gap
Despite this consistency, the gold standard is rarely delivered. A survey of Swedish prosthetic and orthotic clinics found that 86% of practitioners treated plantar neuropathic forefoot ulcers with modified off-the-shelf footwear and insoles—precisely the approach IWGDF recommends against—while only 20% offered total contact casting and none used a non-removable knee-high walker (Gigante et al., Diabetes/Metabolism Research and Reviews, 2023). Many clinicians were unaware that the TCC and non-removable walkers represent the standard of care. Barriers include the time and skill required to apply a cast safely, concerns about complications in fragile skin, patient reluctance, and the effect of a heavy cast on daily activity and transportation. The result is a striking inversion: the least effective devices are used most, and the most effective devices least.
Offloading beyond the ulcer
Offloading also has a role in the earliest stage of Charcot neuro-osteoarthropathy, a destructive process in which the neuropathic foot fractures and collapses. A pilot cohort found that immobilizing the foot with a total contact cast during the inflammatory stage 0—before fractures or deformity appear on imaging—was associated with shorter total casting duration, a lower risk of a new Charcot event, and less need for reconstructive surgery than treatment begun at a later stage (Schoug et al., Diabetes Care, 2024). This reinforces a broader principle: mechanical unloading is most valuable when it is applied early and consistently. Once an ulcer heals, the work shifts to prevention, where properly fitted therapeutic footwear and custom insoles reduce recurrence by managing the same elevated pressures that caused the original wound.
Key takeaways
Offloading is a decisive, evidence-based determinant of whether a plantar diabetic foot ulcer heals. Non-removable knee-high devices—the total contact cast foremost among them—are the best-supported option for uncomplicated neuropathic forefoot ulcers, chiefly because they guarantee that pressure relief is applied with every step. The persistent gap between what the evidence recommends and what is delivered in everyday practice represents one of the clearest opportunities to improve healing rates and reduce amputations. Early, consistent unloading—whether for an established ulcer or an acute Charcot foot—offers the greatest benefit, and durable prevention depends on carrying appropriate pressure management into long-term footwear.
References
Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. Journal of Vascular Surgery. 2016;63(2 Suppl):3S–21S.
Schaper NC, van Netten JJ, Apelqvist J, Bus SA, Hinchliffe RJ, Lipsky BA. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes/Metabolism Research and Reviews. 2020;36(S1):e3266.
Bus SA, Monteiro-Soares M, Game F, et al. Standards for the development and methodology of the 2023 IWGDF guidelines. Diabetes/Metabolism Research and Reviews. 2023;40(3):e3656.
Carter SL, Law JHM, Seyler N, et al. Removable and Nonremovable Off-Loading Devices. Journal of the American Podiatric Medical Association. 2025;115(3).
Vierhout BP, Visser R, Hutting KH, El Moumni M, van Baal JG, de Vries JPPM. Comparing a non-removable total contact cast with a non-removable softcast in diabetic foot ulcers: A retrospective study of a prospective database. Diabetes Research and Clinical Practice. 2022;191:110036.
Gigante I, Sigurjónsdóttir ED, Jarl G, Hellstrand Tang U. Offloading of diabetes-related neuropathic foot ulcers at Swedish prosthetic and orthotic clinics. Diabetes/Metabolism Research and Reviews. 2023;39(4):e3611.
Schoug J, Katzman P, Fagher K, Löndahl M. Charcot Foot Offloading in Stage 0 Is Associated With Shorter Total Contact Cast Treatment and Lower Risk of Recurrence and Reconstructive Surgery: A Pilot Study. Diabetes Care. 2024;47(2):252–258.
Comments
